Neuren Pharmaceuticals Limited (NURPF)
USD 7.63
(10.58%)
USD 7.63
(10.58%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 199.26 Million AUD | 12584.02% |
| 2022 | -1.59 Million AUD | 86.04% |
| 2021 | -8.22 Million AUD | -19.99% |
| 2020 | -8.8 Million AUD | 17.67% |
| 2019 | -11.07 Million AUD | -315.51% |
| 2018 | 5.89 Million AUD | 186.64% |
| 2017 | -6.19 Million AUD | 59.14% |
| 2016 | -11.93 Million AUD | 12.09% |
| 2015 | -15.49 Million AUD | -37.77% |
| 2014 | -9.62 Million AUD | -38.81% |
| 2013 | -6.22 Million AUD | 1.05% |
| 2012 | -9.11 Million AUD | -108.1% |
| 2011 | -4.38 Million AUD | 4.5% |
| 2010 | -4.58 Million AUD | -820.1% |
| 2009 | 481.62 Thousand AUD | 107.66% |
| 2008 | -8.31 Million AUD | 25.8% |
| 2007 | -11.2 Million AUD | 1.66% |
| 2006 | -11.39 Million AUD | -8.81% |
| 2005 | -9.69 Million AUD | -72.5% |
| 2004 | -6.57 Million AUD | -314.03% |
| 2003 | 2.83 Million AUD | 33.68% |
| 2002 | 2.12 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.03 Million AUD | -97.3% |
| 2024 Q2 | 2.03 Million AUD | 0.0% |
| 2023 Q1 | 24.07 Million AUD | 318.91% |
| 2023 Q4 | 151.09 Million AUD | 99.98% |
| 2023 FY | - AUD | 12584.02% |
| 2023 Q3 | 75.55 Million AUD | 56.92% |
| 2023 Q2 | 48.14 Million AUD | 100.0% |
| 2022 Q2 | -7.33 Million AUD | -100.0% |
| 2022 Q1 | -3.66 Million AUD | -13.58% |
| 2022 Q3 | 3.3 Million AUD | 145.08% |
| 2022 Q4 | 5.74 Million AUD | 73.86% |
| 2022 FY | - AUD | 86.04% |
| 2021 Q3 | -15.5 Thousand AUD | 99.81% |
| 2021 FY | - AUD | -19.99% |
| 2021 Q4 | -3.22 Million AUD | -20725.81% |
| 2021 Q1 | -4.09 Million AUD | 2.64% |
| 2021 Q2 | -8.19 Million AUD | -100.0% |
| 2020 Q2 | -5.31 Million AUD | -100.0% |
| 2020 Q4 | -4.2 Million AUD | -141.08% |
| 2020 Q3 | -1.74 Million AUD | 67.14% |
| 2020 Q1 | -2.65 Million AUD | 27.49% |
| 2020 FY | - AUD | 17.67% |
| 2019 FY | - AUD | -315.51% |
| 2019 Q2 | -7.9 Million AUD | -100.0% |
| 2019 Q3 | -1.58 Million AUD | 79.96% |
| 2019 Q1 | -3.95 Million AUD | -181.07% |
| 2019 Q4 | -3.66 Million AUD | -131.25% |
| 2018 Q3 | 4.87 Million AUD | 352.76% |
| 2018 Q1 | -1.92 Million AUD | -50.37% |
| 2018 Q4 | 4.87 Million AUD | 0.0% |
| 2018 FY | - AUD | 186.64% |
| 2018 Q2 | -1.92 Million AUD | 0.0% |
| 2017 Q1 | -1.71 Million AUD | 10.32% |
| 2017 FY | - AUD | 59.14% |
| 2017 Q3 | -1.28 Million AUD | 25.24% |
| 2017 Q2 | -1.71 Million AUD | 0.0% |
| 2017 Q4 | -1.28 Million AUD | 0.0% |
| 2016 Q2 | -4.05 Million AUD | 0.0% |
| 2016 FY | - AUD | 12.09% |
| 2016 Q1 | -4.05 Million AUD | 10.03% |
| 2016 Q4 | -1.91 Million AUD | 0.0% |
| 2016 Q3 | -1.91 Million AUD | 52.84% |
| 2015 FY | - AUD | -37.77% |
| 2015 Q4 | -4.5 Million AUD | 0.0% |
| 2015 Q1 | -3.23 Million AUD | -23.71% |
| 2015 Q2 | -3.23 Million AUD | 0.0% |
| 2015 Q3 | -4.5 Million AUD | -39.26% |
| 2014 Q3 | -2.61 Million AUD | -19.15% |
| 2014 Q1 | -2.19 Million AUD | -25.38% |
| 2014 Q4 | -2.61 Million AUD | 0.0% |
| 2014 FY | - AUD | -38.81% |
| 2014 Q2 | -2.19 Million AUD | 0.0% |
| 2013 Q3 | -1.75 Million AUD | -28.79% |
| 2013 FY | - AUD | 1.05% |
| 2013 Q2 | -1.36 Million AUD | 0.0% |
| 2013 Q1 | -1.36 Million AUD | 0.0% |
| 2013 Q4 | -1.75 Million AUD | 0.0% |
| 2012 FY | - AUD | -108.1% |
| 2011 FY | - AUD | 4.5% |
| 2010 FY | - AUD | -820.1% |
| 2009 FY | - AUD | 107.66% |
| 2008 FY | - AUD | 25.8% |
| 2007 FY | - AUD | 1.66% |
| 2006 FY | - AUD | -8.81% |
| 2005 FY | - AUD | -72.5% |
| 2004 FY | - AUD | -314.03% |
| 2003 FY | - AUD | 33.68% |
| 2002 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.74 Million USD | 11486.407% |
| Skye Bioscience, Inc. | -13.54 Million USD | 1570.834% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | -111.895% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -37679.585% |
| Qrons Inc. | -40.08 Thousand USD | 497248.275% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 54362.147% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 5229.907% |
| BioStem Technologies, Inc. | -7.55 Million USD | 2737.958% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 21367.113% |
| CSL Limited | 4.78 Billion USD | 95.839% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 460.075% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 1247.162% |
| Rebus Holdings, Inc. | -951 Thousand USD | 21052.892% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 31608.556% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 1355.61% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 380.508% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 3460.854% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 83420.928% |
| SQZ Biotechnologies Company | -64.14 Million USD | 410.662% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 7635.108% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 13072.373% |
| Mesoblast Limited | -62.38 Million USD | 419.383% |
| Marizyme, Inc. | -34.28 Million USD | 681.253% |
| Genus plc | 73.7 Million USD | -170.369% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 3113.862% |
| Pharming Group N.V. | 9.87 Million USD | -1917.434% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 13496.557% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 5717.765% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 2371.569% |
| ContraFect Corporation | -64.99 Million USD | 406.562% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 4502.417% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 14314.643% |
| IMV Inc. | -35.52 Million USD | 660.932% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 8674.761% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 38564.152% |
| ONE Bio Corp. | 13.61 Million USD | -1363.758% |
| Accustem Sciences Inc. | -3.74 Million USD | 5418.732% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 513.175% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 15825.433% |
| Q BioMed Inc. | -617.62 Thousand USD | 32362.462% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -5478.443% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 8822.388% |
| Biomind Labs Inc. | -1.03 Million USD | 19360.76% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 602.719% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 6989.334% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 2882.493% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -2963344.378% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 797148.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 8064.23% |
| GB Sciences, Inc. | -1.41 Million USD | 14133.672% |
| Alpha Cognition Inc. | -9.7 Million USD | 2153.062% |
| HST Global, Inc. | -5303.00 USD | 3757633.472% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 9787.02% |
| Halberd Corporation | -74.27 Thousand USD | 268361.554% |
| Enzolytics Inc. | -2.12 Million USD | 9490.164% |
| Agentix Corp. | -1.37 Million USD | 14626.053% |
| Resverlogix Corp. | -11.74 Million USD | 1797.002% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 6605.418% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -216.02 Million USD | 192.241% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -16273.213% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | -2150.581% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 13393.829% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -52497.375% |
| AVAX Technologies, Inc. | -6.11 Million USD | 3359.834% |
| Zenith Capital Corp. | -8.6 Million USD | 2415.385% |
| Genscript Biotech Corporation | -248.71 Million USD | 180.115% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 1143903.456% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 8244.908% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 113301.377% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 10473.307% |
| Kadimastem Ltd | -2.62 Million USD | 7692.724% |
| Helix BioMedix, Inc. | -1.04 Million USD | 19144.224% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 110136.005% |
| LadRx Corporation | 412.28 Thousand USD | -48231.365% |
| Cell Source, Inc. | -4.27 Million USD | 4763.798% |
| Regen BioPharma, Inc. | 1.46 Million USD | -13492.632% |
| NovAccess Global Inc. | -1.03 Million USD | 19356.144% |
| Affymax, Inc. | -14.29 Million USD | 1493.928% |
| Itoco Inc. | -1.86 Million USD | 10761.452% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 52589.858% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 17955.018% |
| Mobile Lads Corp. | -2.24 Million USD | 8991.025% |
| CytoDyn Inc. | -18.02 Million USD | 1205.23% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 252237.823% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 1629521.866% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 41127.594% |
| SYBLEU INC | -141.57 Thousand USD | 140850.577% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 18862.724% |
| International Stem Cell Corporation | 202 Thousand USD | -98544.554% |
| Bioxytran, Inc. | -3.82 Million USD | 5316.082% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 378637.234% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 8193.725% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 655.527% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 442904.444% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 7377.648% |
| Neutra Corp. | -181.24 Thousand USD | 110039.475% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 1088.452% |
| PureTech Health plc | -11.62 Million USD | 1813.787% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 1088.52% |
| IXICO plc | -707 Thousand USD | 28284.158% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 2692.869% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 512.158% |
| CSL Limited | 4.73 Billion USD | 95.79% |
| Cellectis S.A. | -92.63 Million USD | 315.102% |